Innovent Biologics Inc logo

1801 - Innovent Biologics Inc News Story

HK$34.95 -2.4  -6.3%

Last Trade - 5:25am

Sector
Healthcare
Size
Large Cap
Market Cap £4.98bn
Enterprise Value £4.69bn
Revenue £38.7m
Position in Universe 240th / 5984

BRIEF-Innovent Biologics Announces FDA Acceptance Of NDA For Pemigatinib In Patients With Previously Treated, Locally Advanced Or Metastatic Cholangiocarcinoma With FGFR2 Fusions Or Rearrangements

Mon 2nd December, 2019 12:04am
Dec 2 (Reuters) - Innovent Biologics Inc  1801.HK :
    * INNOVENT BIOLOGICS ANNOUNCES FDA ACCEPTANCE OF NDA FOR PEMIGATINIB IN PATIENTS WITH
PREVIOUSLY
TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH FGFR2 FUSIONS OR REARRANGEMENTS

Source text for Eikon:  ID:nPn5srxPZa 
Further company coverage:  1801.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.